Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 418.84 0.35% 1.46
REGN closed up 0.35 percent on Friday, January 18, 2019, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical REGN trend table...

Date Alert Name Type % Chg
Jan 18 New 52 Week Closing High Bullish 0.00%
Jan 18 New 52 Week High Strength 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 New 52 Week Closing High Bullish 0.35%
Jan 17 180 Bullish Setup Bullish Swing Setup 0.35%
Jan 17 Reversal New Highs Setup Bullish Swing Setup 0.35%
Jan 17 New 52 Week High Strength 0.35%
Jan 17 Outside Day Range Expansion 0.35%
Jan 17 Overbought Stochastic Strength 0.35%
Jan 16 Cup with Handle Other 3.53%

Older signals for REGN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Is REGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 420.48
52 Week Low 281.89
Average Volume 730,566
200-Day Moving Average 356.2533
50-Day Moving Average 370.4244
20-Day Moving Average 385.2205
10-Day Moving Average 405.667
Average True Range 12.1954
ADX 28.38
+DI 29.4491
-DI 11.4279
Chandelier Exit (Long, 3 ATRs ) 383.8938
Chandelier Exit (Short, 3 ATRs ) 375.7162
Upper Bollinger Band 432.6203
Lower Bollinger Band 337.8207
Percent B (%b) 0.85
BandWidth 24.609178
MACD Line 12.8614
MACD Signal Line 9.99
MACD Histogram 2.8714
Fundamentals Value
Market Cap 44.41 Billion
Num Shares 106 Million
EPS 9.97
Price-to-Earnings (P/E) Ratio 42.01
Price-to-Sales 8.43
Price-to-Book 7.99
PEG Ratio 1.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 434.56
Resistance 3 (R3) 433.36 426.92 431.94
Resistance 2 (R2) 426.92 422.92 427.52 431.07
Resistance 1 (R1) 422.88 420.44 419.66 424.08 430.19
Pivot Point 416.44 416.44 414.83 417.04 416.44
Support 1 (S1) 412.40 412.44 409.18 413.60 407.49
Support 2 (S2) 405.96 409.96 406.56 406.61
Support 3 (S3) 401.92 405.96 405.74
Support 4 (S4) 403.12